Research Analysts Offer Predictions for MCRB FY2025 Earnings
Seres Therapeutics, Inc. (NASDAQ:MCRB – Free Report) – Stock analysts at Chardan Capital increased their FY2025 earnings per share (EPS) estimates for shares of Seres Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will post earnings per share of ($0.57) […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Free Report) – Stock analysts at Chardan Capital increased their FY2025 earnings per share (EPS) estimates for shares of Seres Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will post earnings per share of ($0.57) […]
